Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Early Hum Dev. 2023 Sep;184:105833. doi: 10.1016/j.earlhumdev.2023.105833. Epub 2023 Jul 26.
Necrotizing enterocolitis (NEC) is a severe gastrointestinal disorder occurring in newborns, with a mortality rate ranging from 20 % to 30 %. The existing therapeutic approaches for NEC are limited in their effectiveness. Various factors contribute to the development of NEC, including disruption of barrier function, dysregulation of the intestinal immune system, and abnormal colonization of the intestinal microbiota. Researchers have shown considerable interest in exploring the therapeutic potential of the constituents present in human breast milk (HBM) for treating NEC. HBM contains numerous bioactive components, such as exosomes, growth factors, and oligosaccharides. However, the precise mechanisms by which HBM exerts its protective effects against NEC remain incompletely understood. In this study, our objective was to comprehensively review the bioactive substances present in HBM, aiming to facilitate the development of novel therapeutic strategies for NEC.
坏死性小肠结肠炎（NEC）是一种发生在新生儿中的严重胃肠道疾病，死亡率在 20%至 30%之间。目前针对 NEC 的治疗方法效果有限。多种因素可导致 NEC 的发生，包括屏障功能障碍、肠道免疫系统失调和肠道微生物菌群异常定植。研究人员对探索人乳（HBM）中成分治疗 NEC 的治疗潜力表现出极大的兴趣。HBM 含有许多生物活性成分，如外泌体、生长因子和低聚糖。然而，HBM 发挥其对 NEC 的保护作用的确切机制仍不完全清楚。在这项研究中，我们的目的是全面综述 HBM 中的生物活性物质，旨在为 NEC 的新型治疗策略的发展提供便利。
